Abstract: Pharmaceutical compositions of topiramate for once-a-day oral administration are provided. The formulations comprise a sustained-release component and an optional immediate-release component, the compositions of which can be selectively adjusted, respectively, to release the active ingredient along a pre-determined release profile. Method of treating or preventing pathological disorders in mammalian subjects comprising the administration of the novel formulations disclosed herein is also provided.

Abstract: The invention relates to a method for making composite active particles for use in a pharmaceutical composition for pulmonary administration, the method comprising a milling step in which particles of active material are milled in the presence of particles of an additive material which is suitable for the promotion of the dispersal of the composite active particles upon actuation of an inhaler. The invention also relates to compositions for inhalation prepared by the method.

Abstract: In one aspect, a particle comprising a core containing at least one pharmaceutically active agent and a coating covering the surface of the particle that comprises a biocompatible adhesive polymer is provided. The core may comprise two or more components, such as two pharmaceutically active agents or a pharmaceutically active agent and a major constituent of the core, having at least one dissimilar chemical or physical property (e.g., molecular weight, solubility, c Log P). In some such embodiments, placement of the uncoated core in certain environments results in the rapid release of a component (e.g., a pharmaceutically active agent) from and/or destabilization and breakdown of the core. In some embodiments, the biocompatible adhesive polymer in the coating acts as a molecular glue to stabilize the core and/or alter the release kinetics of at least one pharmaceutically active agent.

Abstract: Disclosed are conjugated polymer nanoparticles and a method of producing the same. The conjugated polymer nanoparticles include a conjugated polymer, fatty acid and an amphiphile polymer. The conjugated polymer nanoparticles can be doped even under a neutral environment, thus exhibiting high electrical conductivity and exerting absorbance properties in the near-infrared band even under a neutral environment such as in vivo.

Abstract: A pharmaceutical dosage form includes an effective amount of L-menthol for treating a gastrointestinal disorder. The L-menthol is within a plurality of particulates having a core including crystalline L-menthol dissolved in a terpene-based essential oil. A proteinaceous coating of a continuous film of proteinaceous material is over the core.

Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the treatment of atonic seizures. In particular the CBD appears particularly effective in reducing atonic seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; Doose Syndrome; Aicardi syndrome; CDKL5 and Dup15q in comparison to other seizure types. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).

Abstract: A dry consumable preparation and related methods are disclosed. The preparation has a bulking agent, and a cannabinoid and/or a cannabinoid extract containing one or more cannabinoids plated onto the bulking agent. The preparation also has an effervescence agent. The effervescence agent has sodium bicarbonate, potassium bicarbonate, and at least one acid, the at least one acid having at least one of citric acid, tartaric acid, or malic acid. The effervescence agent further has a ratio of sodium bicarbonate to potassium bicarbonate to the acid(s) that creates a chemical pH buffering system at a targeted pH range when the dry consumable preparation is added to a targeted amount of water.

Abstract: A method of treating a disease state or condition in mammals other than humans via topical brainstem afferent stimulation therapy via the administration of a cannabinoid drug(s) to the back of the neck region and/or spine to provide regional neuro-affective therapy is disclosed. In certain preferred embodiments, the cannabinoid drug(s) are not psychoactive or substantially not psychoactive. In certain embodiments, the cannabinoid drug(s) are incorporated into a pharmaceutically acceptable topical carrier, e.g., a cream or mousse. In certain preferred embodiments, the cannabinoid drug(s) comprises cannabidiol.

Abstract: Described herein are methods, compositions, systems, and kits that effectively deliver a laxative to a patient along with effective electrolyte replenishment by delivering both a laxative and electrolytes via a food item. The food item is prepared by either combining, mixing, or integrating the ingredients that form the food item together with one of or both of a laxative and electrolytes so that the ingredients in the food item either eliminate or significantly reduce the poor taste associated with either the electrolytes or the laxative. Eliminating or reducing the poor taste associated with either electrolytes or laxative, greatly improves patient satisfaction and compliance with ingesting these substances in order to, for example, prepare the GI tract of the patient for a medical or surgical procedure.

Abstract: The present disclosure relates to a compound, method of making and method of using such compound preferably in the form of a dietary supplement. The composition, when administered, is capable of treating arthritis and various joint-related pain syndromes. The unique combination of the composition is preferably administered orally. A preferred composition is comprised of at least 10 to 200 mcg of selenium, from about 200 to 1200 mg of MSM, from about 100 to 900 mg of boswellia, from about 1 to 5 mg of type II collagen, from about 25 to 200 mg of hyaluronic acid, and from about 50 to 500 mg of ginger.

Abstract: Methods and materials that can be used to regulate macrophage activation are described. Methods can utilize emodin to bi-directionally modulate macrophage activation and return macrophage phenotype to a homeostatic center (e.g., between M1 and M2 phenotypes) in various environmental settings. Methods can target multiple pathologies within a same individual. Methods can be utilized to inhibit macrophage phenotype activation and affect downstream response to phenotype inducing stimulus, thereby altering macrophage memory.

Abstract: The present invention relates to dexmecamylamine and the use of dexmecamylamine, substantially free of exo-R-mecamylamine, in the treatment of hyperhidrosis.

Abstract: Dosage forms and treatment regimens employing dasotraline for treating Attention Deficit Hyperactivity Disorder (ADHD) are disclosed. The compositions described herein exhibit no abuse potential.

Abstract: Dosage forms and treatment regimens employing dasotraline for treating Attention Deficit Hyperactivity Disorder (ADHD) are disclosed. The compositions described herein exhibit no abuse potential.

Abstract: The present invention relates to a novel process used for the preparation of dry powder formulations for inhalation.

Abstract: Disclosed is a compound of formula (Ia) for the use thereof in the treatment or prevention of diseases relating to the instability of mitochondrial DNA.

Abstract: Compositions, formulations, methods, and systems for treating regional fat deposits comprise contacting a targeted fat deposit with a composition comprising long acting beta-2 adrenergic receptor agonist and a compound that reduces desensitization of the target tissue to the long acting beta-2 adrenergic receptor agonist, for example, glucocorticosteroids and/or ketotifen. Embodiments of the composition are administered, for example, by injection, and/or transdermally.

Abstract: Dapsone compositions can be useful for treating acne. The methods and formulations disclosed herein show efficacy for treating acne vulgaris and/or post inflammatory hyperpigmentation.

Abstract: The present invention provides compositions and methods for relieving pain at a site in a human or animal in need thereof by administering at a discrete site in a human or animal in need thereof a dose of capsaicin in an amount effective to denervate a discrete site without eliciting an effect outside the discrete location, the dose of capsaicin ranging from 1 ?g to 3000 ?g.

Abstract: Disclosed are compositions and methods for modulating cancer stem cells. More particularly, the present invention discloses the use of lysine demethylase (LSD) inhibitors and protein kinase C theta inhibitors (PKC-?) for inhibiting the growth of LSD- and/or PKC-?-overexpressing cells including cancer stem cells, for enhancing the biological effects of chemotherapeutic drugs or irradiation on cancer cells, for treating cancer, including non-metastatic and metastatic cancer and/or for preventing cancer recurrence.

Abstract: This document provides methods and materials for reducing ischemia-reperfusion injury. For example, methods and materials for administering ABA to reduce tissue injury caused by reperfusion following ischemia are provided.

Abstract: A composition comprising a purified extract isolated from Pseudolysimachion rotundum var. subintegrum containing abundant amount of active ingredient or the compounds isolated therefrom as an active ingredient for treating a chronic obstructive pulmonary disease and the use thereof. Inventive purified extract and compounds showed potent anti-COPD activity without beta-2-receptor agonistic response through various in vivo tests as well as in vitro test. Therefore, it can be used as the therapeutics or functional health food for treating and preventing chronic obstructive pulmonary disease (COPD).

Abstract: The present disclosure provides methods for adjusting the dosage of PAA prodrugs (e.g., HPN-100, PBA) based on measurement of PAA and PAGN in plasma and calculating the PAA:PAGN ratio so as to determine whether PAA to PAGN conversion is saturated.

Abstract: Compositions including an odd chain fatty acid, and salts and derivatives thereof, and methods for metabolic syndrome treatment and prophylaxis are provided, including compositions and methods for treating diabetes, obesity, hyperferritinemia, elevated insulin, glucose intolerance, dyslipidemia and related conditions. Methods for the diagnosis and monitoring of metabolic syndrome are also provided.

Abstract: Provided are methods of increasing metabolic maturation of an immature hepatocyte, by contacting an immature hepatocyte which expresses alpha-fetoprotein (AFP) and albumin with an effective amount of a fatty acid or a small molecule selected from the group consisting of: an amphipathic carboxylic acid, Thiazolidinedione (TZD), WY-14643 (Pirinixic Acid), GW409544, GW6471, Leukotriene B4, GW 7647, Perfluorooctanesulfonic Acid, Perfluorooctanoic Acid, CP-775146, CP-865520, UNII-999KY5ZIGB, and Gemfibrozil. Also provided are isolated hepatocytes and uses thereof.

Abstract: This disclosure relates to compositions for use in treatment of Alzheimer's Disease, and/or a ocular and retinal degenerative disease, such as age related macular degeneration. The described compositions include effective amounts of LLMe, the hydrobromide form thereof, or functional derivatives thereof. Methods of treatment of a retinal degenerative disease of Alzheimer's Disease using the described compositions are also provided.

Abstract: Provided are methods for delaying the onset of anesthesia in a subject.

Abstract: Beta-hydroxybutyrate mineral salts in combination with medium chain fatty acids or an ester thereof such as medium chain triglycerides were used to induce ketosis, achieving blood ketone levels of (2-7 mmol/L), with or without dietary restriction. The combination results in substantial improvements in metabolic biomarkers related to insulin resistance, diabetes, weight loss, and physical performance in a short period of time. Further, use of these supplements to achieve ketosis yields a significant elevation of blood ketones and reduction of blood glucose levels. Use of these substances does not adversely affect lipid profiles. By initiating rapid ketosis and accelerating the rate of ketoadaptation, this invention is useful for the avoidance of glucose withdrawal symptoms commonly experienced by individuals initiating a ketogenic diet, and minimizes the loss of lean body mass during dietary restriction.

Abstract: The present invention relates to solid forms of (S)—N-(4-cyano-3-(trifluoromethyl)phenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide and process for producing the same.

Abstract: The use of dianhydrogalactitol provides a novel therapeutic modality for the treatment of glioblastoma multiforme and medulloblastoma. Dianhydrogalactitol acts as an alkylating agent on DNA that creates N7 methylation. Dianhydrogalactitol is effective in suppressing the growth of cancer stem cells and is active against tumors that are refractory to temozolomide; the drug acts independently of the MGMT repair mechanism.

Abstract: Described herein are salts of 3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide, in particular that of formula (I): wherein HA is naphthalene-1,5-disulfonic acid, naphthalene-2-sulfonic acid, oxalic acid, benzenesulfonic acid, or sulfuric acid, or hydrates thereof, and crystalline forms thereof characterized by the powder X-ray diffraction diagram and the 13C CP/MAS NMR solid state spectrum. Also described are compositions, methods of use and preparation thereof.

Abstract: The present invention relates to methods for preventing or treating acute or chronic heart failure and for reducing the risk of cardiovascular death, hospitalization for heart failure and other conditions in patients with preserved or reduced ejection fraction by administering empagliflozin to the patient.

Abstract: Disclosed herein are new compositions comprising a purified cannabinoid and a purified terpene. In one embodiment, the compositions comprise one or more purified cannabinoids. In one embodiment, the compositions comprise one or more purified cannabinoids in combination with one or more purified terpenes. In one embodiment, the compositions comprise unnaturally occurring ratios. In one embodiment, the compositions comprise unnaturally occurring concentrations. In one embodiment, the compositions comprise unexpected and/or synergistic effects.

Abstract: The present invention relates to a method for treating Alzheimer's disease and 2,3-BPG metabolic disorder induced morbidities, comprising administrating a phthalide compound to an Alzheimer's disease patient or a patient having 2,3-BPG metabolic disorder induced morbidities, wherein the method is characterized by that the phthalide compound has the same effect as 2,3-BPG on modulating hemoglobin to reduce its oxygen affinity and can thus act as a 2,3-BPG functional substitute when the 2,3-BPG concentration is too low in the Alzheimer's disease patient or in the patient having 2,3-BPG metabolic disorder induced morbidities to maintain the normal oxygen release function of hemoglobin and therefore to maintain the normal cellular oxygenation level.

Abstract: The present invention relates to a method for substituting for or acting with the hyperbaric oxygen therapy to improve hypoxia, comprising the step of: administrating a phthalide compound to a subject in need thereof, wherein the phthalide compound can increase the oxygen release efficiency of blood hemoglobin (Hb) in the subject and further increase the cellular oxygenation level, and when the phthalide compound substitutes for or act with the hyperbaric oxygen therapy, the common adverse side effects of the hyperbaric oxygen therapy, such as barotrauma, decompression sickness and oxygen poisoning, are prevented. The phthalide compound is used to substitute for or act with 2,3-BPG, to modulate and decrease the oxygen affinity of hemoglobin (Hb), to increase the oxygen release efficiency of hemoglobin (Hb) to tissue cells, thereby achieving a normal cellular oxygenation level and maintaining the cellular oxygenation level in a normal range.

Abstract: The present invention relates to a method for preventing cancer by using a phthalide compound, wherein the phthalide compound has an effect of increasing the oxygen release efficiency of hemoglobin (Hb) of a subject to increase the oxygenation level of organs and tissue cells, thereby preventing the cellular oxygenation level against falling below the critical cellular oxygen requirements under which the normal cells can turn cancerous. Although cancer may be caused by a variety of reasons, including congenital inheritance, external environment, air pollution or poor living and dietary habits, there is only one primary and common reason in causing cancers, the excessively low cellular oxygenation level. When the oxygenation level of any cell falls below 60% of its physiological oxygen requirements, the normal cell may turn cancerous.

Abstract: The present invention is related to a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof. The present invention is further related to a method of healing and/or inhibiting formation of scar tissue in an external wound of a subject comprising topically administering to the external wound of the subject an effective amount of a compositing containing a compound that binds FK506 binding protein 4.

Abstract: The present invention relates to the stable pharmaceutical composition of a suitable hypolipidemic agent. Preferably, the present invention discloses novel formulations of the compound of formula (I), or pharmaceutically acceptable salts of compounds of formula (I). More particularly the present invention relates to the stable pharmaceutical composition of compounds of formula (I) comprising compounds of formula (I) or its pharmaceutically acceptable salts, wherein the pH of the formulation is maintained above 7.

Abstract: Provided herein are stable enalapril oral liquid formulations. Also provided herein are methods of using enalapril oral liquid formulations for the treatment of certain diseases including hypertension, heart failure and asymptomatic left ventricular dysfunction.

Abstract: This invention relates to 2-Aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides of formula 1 and their use as inhibitors of Cathepsin C, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of diseases connected with dipeptidyl peptidase I activity, e.g. respiratory diseases.

Abstract: The present invention provides compounds and/or compositions that modulate PP2A methylation and/or activity and methods for preparing the same, which are useful for modulating the demethylation of PP2A, modulating the methylation of PP2A and/or modulating the activity of PP2A.

Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity and useful as an agent for the prophylaxis or treatment of Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies, and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof. wherein each symbol is as described in the specification, or a salt thereof.

Abstract: Several embodiments provided herein relate to histamine dosing regimens are and uses of such regimens in the restoration of histamine balance in subjects suffering from, for example, histapenia and/or histadelia. Several embodiments also relate to the use of histamine dosing regimens for the treatment and/or prevention of migraine headaches.

Abstract: This invention relates to a new use of compounds that are angiotensin II receptor agonists, specifically agonists of the angiotensin II type 2 receptor (the AT2 receptor), and especially agonists that bind selectively to the AT2 receptor, in the treatment of sickle cell disease.

Abstract: A soft chewable pharmaceutical product for delivery of a pharmaceutically acceptable active ingredient to an animal comprising pamoic acid or a pharmaceutically acceptable salt and a process for the manufacture of such soft chewable pharmaceutical product.

Abstract: The invention provides compositions and methods for treating and preventing cancer. The invention relates to compositions and methods for treating subjects having a cancer associated with overexpression of estrogen receptors, especially in males. The invention comprises inhibitors of ER?, inhibitors of TGF?-1, inhibitors of SMAD, or inhibitors of HIF, or a combination thereof. In one embodiment, the invention provides a method of treating renal cancer, including renal cell carcinoma.

Abstract: The present invention provides a compound of Formula (I) or the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are ERK2 inhibitors. The invention also provides a pharmaceutical composition comprising an effective amount of at least one compound of Formula (I) and a pharmaceutically acceptable carrier. The invention also provides a pharmaceutical composition comprising an effective amount of at least one compound of Formula (I) and an effective amount of at least one other pharmaceutically active ingredient (such as, for example, a chemotherapeutic agent), and a pharmaceutically acceptable carrier.

Abstract: One aspect of the invention provides a method for treating or preventing the development of osteoarthritis by administering to a subject in need of such treatment a composition including a therapeutically effective amount of an anti-fibrotic agent. In various embodiments, the anti-fibrotic agent is 5-methyl-1-phenylpyridin-2-one, tranilast, gamma-glutamyl transpeptidase inhibitor, fasudil, CC-930, T-5524, rosiglitazone, tocilizumab, E5564, TAK-242, GKT136901 or bosentan.

Abstract: The present invention pertains to novel treatments of neuropathic pain; in particular chemotherapy induced peripheral neuropathic pain (CIPNP). The invention provides antagonists cytochrome P450 epoxygenases (CYP), and more specifically antagonists of CYP2J2, as therapeutics for use in the treatment of neuropathic pain such as CIPNP. CYP2J2 antagonists were identified to alleviate CIPNP in-vivo, and therefore are provided additionally in combination with chemotherapeutics for the treatment of diseases such as cancer or other proliferative disorders. The CYP2J2 antagonists reduce chemotherapeutic induced pain and therefore allow for a higher dosing of the chemotherapeutic during cancer treatment. In addition the invention relates to the use of CYP2J2 agonists, or metabolites of CYP2J2, for sensitizing TRPV1.

Abstract: This invention relates to novel pharmaceutical compositions comprising a therapeutically effective combination of a dopaminergic stabilizer known as Pridopidine, and an inhibitor of the vesicular monoamine transporter type 2 (VMAT) known as Tetrabenazine. The pharmaceutical compositions for use according to the invention are contemplated particularly useful for improving the symptomatic therapeutic effects, and for reducing the adverse effects, of Tetrabenazine in the treatment of movement disorders, and in particular movement disorders associated with Huntington's disease, Gilles de la Tourette's syndrome, or tardive dyskinesia.